Pancreatic Cancer Research

ResearcherUniversity of ChicagoNo recent work listed

Mitchell C. Posner

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0004-6495-1961; OpenAlex author ID A5079608944. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
52
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper

Papers 10

  1. A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses. Co-author DOI 10.21037/jgo-20-187↗
  2. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Last author DOI 10.1245/s10434-019-07685-1↗
  3. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. Co-author DOI 10.1002/jso.24872↗
  4. Research gaps in pancreatic cancer research and comparative effectiveness research methodologies. First author DOI 10.1007/978-3-319-12553-4_10↗
  5. National assessment of margin status as a quality indicator after pancreatic cancer surgery. Co-author DOI 10.1245/s10434-013-3338-2↗
  6. Supportive care considerations during concurrent chemoradiotherapy for pancreatic adenocarcinoma: lessons learned from clinical experience. Co-author DOI 10.1097/coc.0b013e31823a53ce↗
  7. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Co-author DOI 10.1245/s10434-013-2886-9↗
  8. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer… Co-author DOI 10.1016/j.gie.2011.10.007↗
  9. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACO… Co-author DOI 10.1093/annonc/mdq384↗
  10. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 t… Co-author DOI 10.1245/s10434-010-1282-y↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hedy Lee Kindler · 4 shared papers, 2013–2020 · strength 0.30
  2. Peter W. T. Pisters · 5 shared papers, 2011–2019 · strength 0.20
  3. Stanley L. Liauw · 1 shared paper, 2020 · strength 0.12
  4. Haejin In · 1 shared paper, 2015 · strength 0.11
  5. Robert Marsh · 2 shared papers, 2013–2018 · strength 0.10
  6. Jordan D. Berlin · 2 shared papers, 2013–2019 · strength 0.10
  7. Nipun B. Merchant · 2 shared papers, 2011–2019 · strength 0.10
  8. Ross Allen Abrams · 3 shared papers, 2011–2013 · strength 0.10
  9. Eileen Mary O'Reilly · 2 shared papers, 2011–2019 · strength 0.10
  10. Vincent J. Picozzi · 3 shared papers, 2011–2013 · strength 0.10
  11. Marshall S. Baker · 1 shared paper, 2018 · strength 0.07
  12. Marina Talamonti · 1 shared paper, 2018 · strength 0.07
  13. Kevin King Roggin · 1 shared paper, 2018 · strength 0.07
  14. Jeffrey B. Matthews · 1 shared paper, 2018 · strength 0.07
  15. Daniel V.T. Catenacci · 1 shared paper, 2018 · strength 0.07
  16. Blasé N. Polite · 1 shared paper, 2018 · strength 0.07
  17. Eric Peter Tamm · 1 shared paper, 2019 · strength 0.07
  18. Robert A. Wolff · 1 shared paper, 2019 · strength 0.07
  19. Elliot Newman · 1 shared paper, 2019 · strength 0.07
  20. Vikram Deshpande · 1 shared paper, 2019 · strength 0.07
  21. Douglas B. Evans · 1 shared paper, 2019 · strength 0.07
  22. Malcolm J. Moore · 1 shared paper, 2019 · strength 0.07
  23. Dushyant V. Sahani · 1 shared paper, 2019 · strength 0.07
  24. Laura Williams Goff · 1 shared paper, 2019 · strength 0.07
  25. Alice Chia-Chi Wei · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.